CyPass lowers IOP, avoids need for conventional glaucoma surgery

by: García-Feijoo J,
Implantation of a supraciliary micro-stent may cause fewer complications, lower IOP and reduce medication dependence compared with conventional glaucoma surgery in open-angle glaucoma patients, according to a study.
The multicenter, single-arm interventional DUETTE study evaluated 65 eyes with open-angle glaucoma that were treated with a CyPass micro-stent (Transcend Medical) after topical therapy failed. Fifty-five eyes were available for follow-up at 12 months.
Mean IOP at baseline was 24.5 ± 2.8 mm Hg with a mean number of 2.2 ± 1.1 medications used.
There were no sight-threatening intraoperative complications and no serious device-related ocular adverse events during the 12-month follow-up.
Over the course of the 12 months, seven eyes had an IOP increase of more than 30 mm Hg, four eyes had transient hyphema, and five eyes had cataract progression.
At 12 months postoperatively, mean IOP decreased 34.7% to 16.4 ± 5.5 mm Hg, and mean medication usage decreased an average of 0.8 medications per patient to 1.4 ± 1.3. Both changes were statistically significant.
In eyes that were indicated for conventional glaucoma surgery at the time of enrollment, 83% did not receive secondary glaucoma surgery in the 12-month follow-up. – by Kristie L. Kahl
Disclosure: García-Feijoo reports he is a consultant for Transcend Medical, Glaukos, Alcon, Merck & Co., Bausch + Lomb and Sensimed; received grants from Glaukos, Ivantis, Alcon, Merck & Co, Bausch + Lomb, Sensimed, Sylentis,Pfizer, Allergan, Laboratoires Thea and Solx; and is a speaker for Alcon, Merck & Co. and Abbott Medical Optics. Please see the full study for a list of all other authors’ relevant financial disclosures.
Source: Healio-